Efficacy of On-Demand Asimadoline, a Peripheral κ-Opioid Agonist, in Females With Irritable Bowel Syndrome

Clinical Gastroenterology and Hepatology

Volumn 5, Issue 11, 2007, Pages 1268-1275

  Szarka, Lawrence A ^a   Camilleri, Michael ^a   Burton, Duane ^a   Fox, Jean C ^a   McKinzie, Sanna ^a   Stanislav, Timothy ^a   Simonson, Julie ^a   Sullivan, Nancy ^a   Zinsmeister, Alan R ^b  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

^b Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASIMADOLINE; PLACEBO; ACETAMIDE DERIVATIVE; KAPPA OPIATE RECEPTOR; PYRROLIDINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ANXIETY; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; INTESTINE FUNCTION; IRRITABLE COLON; MAJOR CLINICAL STUDY; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; PERIPHERAL NEUROPATHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SCORING SYSTEM; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT DISEASE; VISUAL ANALOG SCALE; ADOLESCENT; DRUG POTENTIATION; MIDDLE AGED; PAIN ASSESSMENT; PHASE 2 CLINICAL TRIAL; PSYCHOLOGICAL ASPECT;

ACETAMIDES; ADOLESCENT; ADULT; AGED; ANXIETY; DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MIDDLE AGED; PAIN MEASUREMENT; PYRROLIDINES; QUALITY OF LIFE; RECEPTORS, OPIOID, KAPPA;

EID: 35548931920     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2007.07.011     Document Type: Article

References (26)

1. Hungin A.P., Chang L., Locke G.R., et al. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther 21 (2005) 1365-1375
2. Hulisz D. The burden of illness of irritable bowel syndrome: current challenges and hope for the future. J Managed Care Pharmacy 10 (2004) 299-309
3. Holtmann G., Goebell H., and Talley N.J. Functional dyspepsia and irritable bowel syndrome-is there a common pathophysiologic basis?. Am J Gastroenterol 92 (1997) 954-959
4. Trimble K.C., Farouk R., Pryde A., et al. Heightened visceral sensation in functional gastrointestinal disease is not site specific evidence for a generalized disorder of gut sensitivity. Dig Dis Sci 40 (1995) 1607-1613
5. Satoh M., and Minami M. Molecular pharmacology of the opioid receptors. Pharmacol Ther 68 (1995) 343-364
6. Gottschlich R., Krug M., Barber A., et al. κ-opioid activity of the four stereoisomers of the peripherally selective κ-agonists, EMD 60,400 and EMD 61,753. Chirality 6 (1994) 685-689
7. Simonin F., Gaveriaux-Ruff C., Befort K., et al. κ-opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. Proc Natl Acad Sci U S A 92 (1995) 7006-7010
8. Barber A., Bartoszyk G.D., Bender H.M., et al. A pharmacological profile of the novel, peripherally-selective κ-opioid receptor agonist, EMD 61753. Br J Pharmacol 113 (1994) 1317-1327
9. Asimadoline (EMD 61 753) investigators brochure. Darmstadt: E. Merck, 2001.
10. Burton M.B., and Gebhart G.F. Effects of κ-opioid receptor agonists on responses to colorectal distention in rats with and without acute colonic inflammation. J Pharmacol Exp Ther 285 (1998) 707-715
11. Delgado-Aros S., Chial H.J., Camilleri M., et al. Effects of a κ-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. Am J Physiol 284 (2003) G558-G566
12. Delgado-Aros S., Chial H.J., Cremonini F., et al. Effects of asimadoline, a κ-opioid agonist, on satiation and postprandial symptoms in health. Aliment Pharmacol Ther 18 (2003) 507-514
13. Delvaux M., Beck A., Jacob J., et al. Effect of asimadoline, a κ opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 20 (2004) 237-246
14. Hahn B., Watson M., Yan S., et al. Irritable bowel syndrome, symptom patterns: frequency, duration, and severity. Dig Dis Sci 43 (1998) 2714-2718
15. Zigmond A.S., and Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr Scand 67 (1983) 361-370
16. Patrick D.L., Drossman D.A., Frederick I.O., et al. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 43 (1998) 400-411
17. Heaton K.W., Ghosh S., and Braddon F.E. How bad are the symptoms and bowel dysfunction of patients with the irritable bowel syndrome?. A prospective, controlled study with emphasis on stool form. Gut 32 (1991) 73-79
18. Coulie B., Szarka L.A., Camilleri M., et al. Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans. Gastroenterology 119 (2000) 41-50
19. Camilleri M., Northcutt A.R., Kong S., et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 355 (2000) 1035-1040
20. Andresen V., and Camilleri M. Irritable bowel syndrome: recent and novel therapeutic approaches. Drugs 66 (2006) 1073-1088
21. Machelska H., Pfluger M., Weber W., et al. Peripheral effects of the κ-opioid agonist EMD 61753 on pain and inflammation in rats and humans. J Pharmacol Exp Ther 290 (1990) 354-361
22. Crain S.M., and Shen K.F. Opioids can evoke direct receptor-mediated excitatory effects on sensory neurons. Trends Pharmacol Sci 11 (1990) 77-81
23. Dapoigny M., Abitbol J.L., and Fraitag B. Efficacy of peripheral κ agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study. Dig Dis Sci 40 (1995) 2244-2249
24. Callahan M. Irritable bowel syndrome neuropharmacology: a review of approved and investigational compounds. J Clin Gastroenterol 35 (2002) S58-S67
25. Stein C. The control of pain in peripheral tissue by opioids. N Engl J Med 332 (1995) 1685-1690
26. Pasricha P.J. "Kapping" visceral pain in patients with irritable bowel syndrome: does it work?. Gastroenterology 111 (1996) 531-533